Sheyda Abdullaeva

Medical Oncologist

[Sheyda Abdullaeva @SheydaDoc]

In our study, we showed the optimal cut-off value between high and low TIL levels in triple negative breast cancer. TIL >40% is significantly associated with better event-free survival.
#TILs #TNBC #SABCS24

[Yakup Ergün @dr_yakupergun]

Algorithm for Systemic Therapy in Early TNBC

(Based on NCCN and ESMO guidelines; recommendations in gray areas reflect the St. Gallen 2025 consensus and, in part, my own clinical judgment)

[MV Chandrakanth @ChandrakanthMv]

CARBOPLATIN MATTERS: Beyond pCR—Improving Survival in Early TNBC

Carboplatin has long been regarded as a strategy to increase pathologic complete response (pCR) in early triple-negative breast cancer. The PEARLY trial suggests its benefit extends beyond pCR, with a significant improvement in long-term event-free survival.

Key findings
• 868 patients with stage II–III TNBC
• 5-year EFS: 82.3% vs 75.1%
• Absolute EFS gain: +7.2%
• HR 0.67 (33% relative reduction in EFS events)
• Benefit observed in both neoadjuvant and primary surgery → adjuvant settings
• Higher hematologic toxicity, while quality of life and patient-reported neuropathy were preserved

These findings reinforce carboplatin as an evidence-based chemotherapy intensification strategy in early TNBC, particularly when immune checkpoint inhibitors are unavailable or unsuitable.

Reference: Kim GM, et al. PEARLY Trial. Annals of Oncology. 2026.

#BreastCancer #TNBC #MedicalOncology #Oncology #AnnalsOfOncology #MVOnco

[MV Chandrakanth @ChandrakanthMv]

Can we move beyond chemotherapy in first-line metastatic TNBC?

The BEGONIA Arms 7 & 8 study evaluated the chemotherapy-free combination of Dato-DXd + durvalumab, demonstrating encouraging activity with:

• ORR: 79%
• Complete response: 12.9%
• Median PFS: 14.0 months
• Median DoR: 17.6 months
• Activity observed across PD-L1 subgroups.

While these phase Ib/II results are highly promising, they are hypothesis-generating. Randomized phase III trials are essential before changing standard clinical practice.

What are your thoughts on the role of ADC–immunotherapy combinations in first-line mTNBC?

Reference: Schmid P et al. BEGONIA Arms 7 & 8. Annals of Oncology. 2026.

#BreastCancer #TNBC #mTNBC #ADCs #Immunotherapy #DatoDXd #Durvalumab #Oncology #MedTwitter #MVOnco

[MV Chandrakanth @ChandrakanthMv]

• 🇪🇺 European GAMBIT: Large multicenter real-world study of 2,457 TNBC patients; 1,192 achieved pCR.

• pCR ≠ Cure — ~10% still relapse.

• Baseline cN+ + low stromal TILs (<30%) identify the highest-risk subgroup despite pCR.

• Brain becomes the commonest first site of relapse in this subgroup.

• A simple combination of clinical nodal status + stromal TILs may help guide future risk-adapted surveillance and escalation strategies.

📖 Massa D et al. Nature Communications. 2026.

[Paolo Tarantino @PTarantinoMD]

A common worldwide practice is to give chemo prior to ET to patients with untreated HR+ MBC. Multiple randomized studies have now proved that this strategy is inferior. Glad to see the #PADMA study published in @ESMO_Open, showing dramatically longer PFS with ET/palbo vs chemo.

[Yakup Ergün @dr_yakupergun]

#ASCO26

Endocrine resistance is not binary. It is a spectrum.

From the excellent presentation by Dr. Alexandru Eniu👇

[Muhammad Muneeb @im2muneeb]

How to analyze data in minutes?

This tool is used by more than 500,000 researchers.

1. Go to https://t.co/sbnadJ1eRH

2. Click on attach file to upload your data file.

3. Write your prompt for data analysis.

5. AnswerThis will generate variety of graphs for you.

#phd

[Paolo Tarantino @PTarantinoMD]

Adjuvant T-DXd is approved for pts with HER2+ BC and high-risk RD by DB05 criteria. What about pts with lower risk RD? We looked at ~10.000 pts in Flatiron, finding that 52% have low-risk RD, with 3yr DRFS 94%, suggesting that T-DM1 remains an adequate SoC for them. #ASCO26 Ab545

[Movez @0xMovez]

Anthropic pays $750,000+ a year for engineers who can build LLM architectures from scratch.

This 2-hour Stanford lecture gives you the exact pipeline LLM engineers get paid $750K/year for.

Data + architecture + scaling laws + post-training.

Bookmark it & watch today. Then read article below.

[MV Chandrakanth @ChandrakanthMv]

ESMO Breast 2026 — key trials at a glance

• HER2+ trials
• HR+/HER2− trials
• TNBC / ADC / Immunotherapy trials

Major studies, key results, and clinical take-home messages — all in one quick visual summary.

#ESMOBreast2026 #BreastCancer #Oncology #MVOnco

[Swati Gupta @hrswatigupta]

I Cancelled Spotify.
I cancelled Disney+.
I cancelled Apple TV+.

No more paying every month.

Claude transformed my laptop into a free entertainment center.

Here are 8 prompts to create this system:

[Luis Enzo @techluisenzo]

🚨 Stop using Claude like it’s ChatGPT — they’re completely different tools.

Here’s how to set it up the right way in just 10 minutes 📸

(Save this for later 🔖)

[Dr Rishabh Jain @DrRishabhOnco]

PFS2 as a surrogate for OS in breast cancer? 🧠

🆕 ESMO Open 2026 systematic review of 18 RCTs (n = 9,617)

🎯 Question: Can PFS2 reliably predict OS in breast cancer?

📊 Primary analysis
•r = 0.71
•R² = 0.51
→ ~51% of OS variability explained by PFS2

⚠️ Long-term OS validation:
•r = 0.55
•R² = 0.30
→ Signal weakens with maturity

🔬 Surrogacy improves only when:
•PFS2 maturity ≥55% → R² = 0.86
•OS information fraction ≥75% → R² = 0.87

But not consistent in long-term validation.

📌 Interestingly:
PFS1 showed slightly stronger association with OS
•r = 0.77
•R² = 0.60

💡 Takeaway:
PFS2 is context-dependent, not a robust universal surrogate.
Endpoint maturity matters. Clinical setting matters.

Be cautious before accepting PFS2 as a primary decision driver.

#OncoTwitter #MedTwitter #BreastCancer #ClinicalTrials

@OncoAlert @myESMO @ASCO @JCOPO_ASCO @stolaney1 @PTarantinoMD

[ESMO Open @ESMO_Open]

PFS2 as a surrogate endpoint for OS in breast cancer randomized controlled clinical trials in @ESMO_Open. Context-dependent association, stronger association with higher PFS2 maturity and OS information fraction. https://t.co/ViDkQjXjOA

[ESMO Open @ESMO_Open]

ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitors in @ESMO_Open. Evidence-based consensus statements providing guidance on the safety of combining RT with EGFR, ALK, or BRAF/MEK inhibitors. https://t.co/3SKc65HRwt

[Dr Rishabh Jain @DrRishabhOnco]

⚠️ RT + Targeted Therapy = Hidden Toxicity Risk?

New ESMO–ESTRO consensus on combining radiotherapy with:

🔹 EGFR inhibitors
🔹 ALK inhibitors
🔹 BRAF/MEK inhibitors

📄 Review in ESMO Open 2026

🟣 EGFR inhibitors
• ↑ Dermatitis & mucositis risk
• Thoracic RT + osimertinib → high pneumonitis risk
• Major adaptation recommended in most high-dose settings

🔵 ALK inhibitors
• Evidence limited
• Most scenarios → major adaptation advised
• CNS combinations need caution

🔴 BRAF/MEK inhibitors
• Clear ↑ skin toxicity
• High-dose skin RT → avoid combination
• Vemurafenib + skin RT → do NOT combine

@OncoAlert @myESMO @ASCO

[MV Chandrakanth @ChandrakanthMv]

• Pegfilgrastim timing matters
• 24h → higher early WBC spike
• 72h → ↓ bone pain
• 72h → more controlled WBC curve
• No loss of efficacy
Maybe 72 hours is the sweet spot 👇
#MVOnco #Pegfilgrastim #GCSF #Oncology #SupportiveCare #DoseDense

[Harold J. Burstein, MD, PhD, FASCO @DrHBurstein]

The St Gallen Consensus @SG_BCC for early breast cancer still outperforms AI including ChatGPT and Deepseek. For now!

https://t.co/c5pR4XLdNG

@curijoey

[Oscar Arias @OACerebro]

Enjoy!!!

https://t.co/t2HydkblWt

[Oncology Brothers @OncBrothers]

Press release for #LIBRETTO432 is positive (primary end point of Event free survival)! Trending OS but immature right now. Selpercatinib in Adj settings (for 3yrs) status post surgery or radiation for Stage IB-IIIA NSCLC w/ RET fusion-positive disease.

#lcsm #OncTwitter #MedX